NCT01658150

Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder

A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Icahn School of Medicine at Mount Sinai · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder.

Detailed description

The purpose of this study is to evaluate the use of the drug isradipine for cognitive enhancement in patients diagnosed with schizophrenia and schizoaffective disorder. Incomplete treatment response can be common in these disorders. While there are medications that are effective at treating positive symptoms, some other symptoms of the disorders are often left only partially treated (cognitive impairment and negative symptoms). This study will begin to address if the medication isradipine might help to treat some of the cognitive problems associated with schizophrenia and schizoaffective disorder. Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel. It is currently approved by the FDA for hypertension.

Conditions

• Schizophrenia
• Schizoaffective Disorder

Interventions

Type	Name	Description
DRUG	isradipine	Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel

Timeline

• Start date: 2012-09-01
• Primary completion: 2018-01-02
• Completion: 2018-01-02
• First posted: 2012-08-06
• Last updated: 2018-12-05
• Results posted: 2018-12-05

Locations

1 site across 1 country: United States